638 related articles for article (PubMed ID: 29960819)
1. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
3. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
[TBL] [Abstract][Full Text] [Related]
4. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
[TBL] [Abstract][Full Text] [Related]
5. A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma.
Steuer CE; Griffith CC; Nannapaneni S; Patel MR; Liu Y; Magliocca KR; El-Deiry MW; Cohen C; Owonikoko TK; Shin DM; Chen ZG; Saba NF
Mol Cancer Ther; 2018 Mar; 17(3):710-716. PubMed ID: 29440293
[TBL] [Abstract][Full Text] [Related]
6. Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.
Zhu Y; Zhu X; Diao W; Liang Z; Gao Z; Chen X
Clin Oral Investig; 2023 Apr; 27(4):1423-1433. PubMed ID: 36884083
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
8. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
Oguejiofor K; Galletta-Williams H; Dovedi SJ; Roberts DL; Stern PL; West CM
Oncotarget; 2017 Feb; 8(9):14416-14427. PubMed ID: 28122336
[TBL] [Abstract][Full Text] [Related]
9. Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.
Kim HS; Lee JY; Lim SH; Park K; Sun JM; Ko YH; Baek CH; Son YI; Jeong HS; Ahn YC; Lee MY; Hong M; Ahn MJ
Cancer Res Treat; 2016 Apr; 48(2):527-36. PubMed ID: 26511814
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment.
Sato F; Ono T; Kawahara A; Kawaguchi T; Tanaka H; Shimamatsu K; Kakuma T; Akiba J; Umeno H; Yano H
J Clin Pathol; 2019 Aug; 72(8):542-549. PubMed ID: 31113825
[TBL] [Abstract][Full Text] [Related]
11. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
Front Immunol; 2019; 10():1644. PubMed ID: 31379843
[No Abstract] [Full Text] [Related]
12. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
13. PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.
Nagarajan P; El-Hadad C; Gruschkus SK; Ning J; Hudgens CW; Sagiv O; Gross N; Tetzlaff MT; Esmaeli B
Invest Ophthalmol Vis Sci; 2019 May; 60(6):2388-2398. PubMed ID: 31141610
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
Wuerdemann N; Gültekin SE; Pütz K; Wittekindt C; Huebbers CU; Sharma SJ; Eckel H; Schubotz AB; Gattenlöhner S; Büttner R; Speel EJ; Klussmann JP; Wagner S; Quaas A
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718057
[TBL] [Abstract][Full Text] [Related]
15. Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma.
Fukushima Y; Someya M; Nakata K; Hori M; Kitagawa M; Hasegawa T; Tsuchiya T; Gocho T; Ikeda H; Hirohashi Y; Torigoe T; Sugita S; Hasegawa T; Himi T; Sakata KI
Radiother Oncol; 2018 Nov; 129(2):409-414. PubMed ID: 30249348
[TBL] [Abstract][Full Text] [Related]
16. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
17. Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer.
Birtalan E; Danos K; Gurbi B; Brauswetter D; Halasz J; Kalocsane Piurko V; Acs B; Antal B; Mihalyi R; Pato A; Fent Z; Polony G; Timar J; Tamas L
Appl Immunohistochem Mol Morphol; 2018 Aug; 26(7):e79-e85. PubMed ID: 29271789
[TBL] [Abstract][Full Text] [Related]
18. High-Grade Neuroendocrine Carcinoma of the Head and Neck: Human Papillomavirus Status and PD-L1 Expression.
Bahr K; Zimmer S; Springer E; Fottner C; Becker S; Ernst BP; Matthias C; Künzel J
ORL J Otorhinolaryngol Relat Spec; 2019; 81(5-6):309-316. PubMed ID: 31550725
[TBL] [Abstract][Full Text] [Related]
19. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP
Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma.
Jeong JY; Park TI; Ahn D
Anticancer Res; 2020 Jul; 40(7):4001-4010. PubMed ID: 32620644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
